バイオシミュレーション市場規模、シェア、成長分析：製品別、用途別、治療分野別、展開別、価格別、最終用途別、地域別 - 産業予測 2025～2032年

バイオシミュレーションの市場規模は2023年に40億米ドル、予測期間（2025-2032年）のCAGRは17.2%で、2024年の46億9,000万米ドルから2032年には166億9,000万米ドルに成長する見通しです。

シミュレーションソフトウェア市場は、医療アプリケーションの進歩や、自動車、エレクトロニクス、航空宇宙などの分野で広く利用されていることを背景に、大きな成長を遂げています。これらのツールは、システムの挙動や相互作用を分析するための数学的モデルを採用することで、プロトタイプの作成や実世界の対象物のシミュレーションを可能にします。シミュレーションソフトウェアの主な利点には、トレーニングコストや製造コストの削減、機器や材料の品質向上、製品リコールに伴うリスクの最小化などがあります。COVID-19の大流行により、物理的な相互作用を減らしながらプロセスとオペレーションを最適化するデジタル技術の重要性が浮き彫りになり、導入がさらに加速しています。シミュレーションツールは、ヘルスケア専門家のトレーニング、ウイルス拡散のモデル化、パンデミック中に直面した課題に対処するための効果的な戦略の開発に役立っています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• ケーススタディ
• 規制情勢
• 特許分析

バイオシミュレーション市場規模：製品別& CAGR（2025-2032）

• 市場概要
• ソフトウェア
• サービス

バイオシミュレーション市場規模：用途別& CAGR（2025-2032）

• 市場概要
• 医薬品開発
• 創薬
• その他

バイオシミュレーション市場規模：治療分野別& CAGR（2025-2032）

• 市場概要
• 腫瘍学
• 神経学
• 心臓病学
• その他

バイオシミュレーション市場規模：展開別& CAGR（2025-2032）

• 市場概要
• オンプレミス
• クラウドベース

バイオシミュレーション市場規模：価格別& CAGR（2025-2032）

• 市場概要
• サブスクリプション
• 所有

バイオシミュレーション市場規模：最終用途別& CAGR（2025-2032）

• 市場概要
• 製薬・バイオテクノロジー企業
• 契約調査機関（CRO）
• 学術調査機関
• 規制当局

バイオシミュレーション市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Simulations Plus, Inc.（USA）
• Dassault Systemes（France）
• Schrodinger, LLC（USA）
• ACD/Labs（Canada）
• Chemical Computing Group（Canada）
• Physiomics PLC（UK）
• Evidera（USA）
• In Silico Biosciences, Inc.（USA）
• INOSIM Software GmbH（Germany）
• Insilico Biotechnology AG（Germany）
• LeadInvent Technologies（India）
• Rosa & Co. LLC（USA）
• Genedata AG（Switzerland）

結論と提言

Biosimulation Market size was valued at USD 4.0 billion in 2023 and is poised to grow from USD 4.69 billion in 2024 to USD 16.69 billion by 2032, growing at a CAGR of 17.2% during the forecast period (2025-2032).

The simulation software market is witnessing significant growth, driven by advancements in medical applications and widespread utilization across sectors like automotive, electronics, and aerospace. These tools enable the creation of prototypes and the simulation of real-world objects by employing mathematical models to analyze system behaviors and interactions. Key benefits of simulation software include reduced training and manufacturing costs, enhanced equipment and material quality, and minimized risks associated with product recalls. The COVID-19 pandemic has further accelerated adoption, highlighting the importance of digital technologies in optimizing processes and operations while reducing physical interactions. Simulation tools have been instrumental in training healthcare professionals, modeling virus spread, and developing effective strategies to address challenges faced during the pandemic.

Top-down and bottom-up approaches were used to estimate and validate the size of the Biosimulation market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Biosimulation Market Segments Analysis

Global Biosimulation Market is segmented by Product, Application, Therapeutic Area, Deployment Model, Pricing Model, End Use and region. Based on Product, the market is segmented into Software and Services. Based on Application, the market is segmented into Drug Development, Drug Discovery and Others. Based on Therapeutic Area, the market is segmented into Oncology, Neurology, Cardiology and Others. Based on Deployment Model, the market is segmented into On-premise and Cloud-based. Based on Pricing Model, the market is segmented into Subscription and Ownership. Based on End Use, the market is segmented into Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs), Academic & Research Institutes and Regulatory Authorities. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Biosimulation Market

The biosimulation market is significantly driven by the growing demand for cost-effective solutions across various industries, as companies strive to minimize operating expenses. This trend has resulted in an increase in the adoption of simulation software, which allows businesses to conduct virtual testing and analysis. By leveraging these advanced tools, organizations can effectively reduce the expenses associated with physical prototypes and traditional testing methods, leading to substantial savings. Consequently, the ability to perform efficient simulations not only accelerates the development process but also supports businesses in making informed decisions, further propelling the growth of the biosimulation market.

Restraints in the Biosimulation Market

Although biosimulation offers numerous benefits, the considerable initial expenses tied to simulation software pose a notable constraint. The costs related to licensing, necessary hardware upgrades, and employee training can be quite substantial, creating a financial burden, particularly for small and medium-sized enterprises (SMEs). This high upfront investment can deter some companies from adopting such software solutions, especially those operating within tight budgetary constraints. As a result, the financial barrier may restrict the wider implementation of biosimulation technology, hindering its potential growth and utilization in the market for organizations with limited resources.

Market Trends of the Biosimulation Market

The biosimulation market is experiencing significant growth, driven predominantly by the expansion of artificial intelligence (AI) technologies. AI enhances the accuracy and efficiency of biosimulations, delivering predictive insights that are crucial for industries like healthcare and autonomous vehicles, where navigating complex systems is essential. This integration not only streamlines the simulation process but also allows for real-time optimization of performance, making these tools invaluable for research and development. As industries increasingly recognize the strategic advantages offered by AI-driven biosimulations, the market is projected to flourish, attracting investments and fostering innovations that advance scientific discovery and improve outcomes across various applications.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Patent Analysis

Global Biosimulation Market Size by Product & CAGR (2025-2032)

• Market Overview
• Software
• Services

Global Biosimulation Market Size by Application & CAGR (2025-2032)

• Market Overview
• Drug Development
• Drug Discovery
• Others

Global Biosimulation Market Size by Therapeutic Area & CAGR (2025-2032)

• Market Overview
• Oncology
• Neurology
• Cardiology
• Others

Global Biosimulation Market Size by Deployment Model & CAGR (2025-2032)

• Market Overview
• On-premise
• Cloud-based

Global Biosimulation Market Size by Pricing Model & CAGR (2025-2032)

• Market Overview
• Subscription
• Ownership

Global Biosimulation Market Size by End Use & CAGR (2025-2032)

• Market Overview
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations (CROs)
• Academic & Research Institutes
• Regulatory Authorities

Global Biosimulation Market Size & CAGR (2025-2032)

• North America (Product, Application, Therapeutic Area, Deployment Model, Pricing Model, End Use)
  • US
  • Canada
• Europe (Product, Application, Therapeutic Area, Deployment Model, Pricing Model, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Application, Therapeutic Area, Deployment Model, Pricing Model, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Application, Therapeutic Area, Deployment Model, Pricing Model, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Application, Therapeutic Area, Deployment Model, Pricing Model, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Simulations Plus, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dassault Systemes (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Schrodinger, LLC (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ACD/Labs (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chemical Computing Group (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Physiomics PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evidera (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• In Silico Biosciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• INOSIM Software GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Insilico Biotechnology AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LeadInvent Technologies (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rosa & Co. LLC (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genedata AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations